GEN Exclusives

More »

GEN News Highlights

More »
Aug 11, 2008

Alnylam and Max Planck Institute Ally to Investigate Uptake of RNAi Drugs

  • Alnylam Pharmaceuticals and Max Planck Institute of Molecular Cell Biology and Genetics are working together to understand the molecular mechanisms behind intracellular transport of siRNA.

    Under the exclusive research agreement, Alnylam scientists will work closely with the laboratory of Marino Zerial, Ph.D., to investigate cellular uptake pathways in a high-throughput manner. Alnylam will have an option on any resulting intellectual property.

    “Through this collaboration,” notes Marino Zerial, Ph.D., research group leader and director at the Max Planck Institute of Molecular Cell Biology and Genetics, “we will increase our understanding of how different siRNA formulations are internalized within cells and then use this knowledge to further optimize approaches for delivery of RNAi therapeutics.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »